

# Gerardo Di Scala

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3470635/publications.pdf>

Version: 2024-02-01

30  
papers

882  
citations

471061

17  
h-index

476904

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1389  
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 infection among patients with systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2020, 19, 102575.	2.5	131
2	Vascular Behçet's syndrome: an update. <i>Internal and Emergency Medicine</i> , 2019, 14, 645-652.	1.0	99
3	Involvement of Hypothalamus Autoimmunity in Patients with Autoimmune Hypopituitarism: Role of Antibodies to Hypothalamic Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3684-3690.	1.8	61
4	Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 1500-1507.	2.9	57
5	Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study. <i>Journal of Autoimmunity</i> , 2019, 97, 108-113.	3.0	50
6	The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 298-304.	1.0	46
7	Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects. <i>Clinical and Experimental Immunology</i> , 2019, 195, 322-333.	1.1	41
8	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCs (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , 2019, 21, 204.	1.6	40
9	Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1098-1104.	0.5	39
10	The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review. <i>Rheumatology International</i> , 2019, 39, 971-990.	1.5	38
11	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. <i>Clinical Rheumatology</i> , 2017, 36, 2063-2069.	1.0	36
12	Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: A cross-sectional study. <i>International Journal of Cardiology</i> , 2019, 274, 1-6.	0.8	32
13	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. <i>Mediators of Inflammation</i> , 2019, 1-8.	1.4	27
14	Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. <i>Journal of Autoimmunity</i> , 2020, 108, 102397.	3.0	26
15	Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab. <i>Clinical Rheumatology</i> , 2018, 37, 1715-1720.	1.0	21
16	Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1736-1737.	0.5	21
17	Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-5.	1.4	20
18	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. <i>Inflammopharmacology</i> , 2020, 28, 711-718.	1.9	19

#	ARTICLE	IF	CITATIONS
19	A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1662-1665.	1.5	17
20	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 762-767.	0.4	10
21	Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network. <i>Internal and Emergency Medicine</i> , 2021, 16, 2163-2171.	1.0	8
22	Impact of cardiovascular and immunologic variables on subclinical carotid atherosclerosis in subjects with anti-phospholipid antibodies. <i>Data in Brief</i> , 2018, 19, 1799-1803.	0.5	7
23	Intravenous immunoglobulin therapy: a snapshot for the internist. <i>Internal and Emergency Medicine</i> , 2019, 14, 1041-1049.	1.0	7
24	Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 1357-1367.	1.0	7
25	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. <i>Israel Medical Association Journal</i> , 2018, 20, 438-441.	0.1	7
26	Low-dose tocilizumab for relapsing giant cell arteritis in the elderly, fragile patient: Beyond the GIACTA trial. <i>Autoimmunity Reviews</i> , 2018, 17, 1265-1267.	2.5	5
27	Behçet's disease as a cause of cerebral sinus vein thrombosis: an emerging role. <i>Rheumatology</i> , 2019, 58, 563-564.	0.9	4
28	Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 995-1002.	0.4	2
29	Old and New Treatment for Behçet's Disease. <i>Rare Diseases of the Immune System</i> , 2014, , 207-216.	0.1	0
30	AB0600...APREMILAST EFFECTIVENESS IN REFRACTORY ORAL AND GENITAL ULCERS OF BEHÇET'S DISEASE: DATA FROM REAL LIFE SETTINGS. , 2019, , .		0